Filippo Pietrantonio, MD

Filippo Pietrantonio, MD, Department of Medical Oncology, Medical Oncology Unit, Milan Fondazione IRCCS Istituto Nazionale dei Tumori, discusses survival rates in patients with colorectal cancer (CRC).

The survival of such patients, says Pietrantonio, is generally poor. Typically, clinical trial data show reported survival rates of up to 5 months. However, he explains, there is some heterogeneity in clinical outcomes, as some patients may actually die sooner, while other patients may have longer survivals even if their disease is defined as refractory.

In order to improve these survival rates, Pietrantonio says that identifying the correct patients that are able to receive further treatments is key. This could be accomplished mainly through clinical selection. Currently, most available drugs cannot rely on biomarkers, thus prognostic stratification is, at present, the most important thing to do.

Videos

Filippo Pietrantonio, MD, Department of Medical Oncology, Medical Oncology Unit, Milan Fondazione IRCCS Istituto Nazionale dei Tumori, discusses survival rates in patients with colorectal cancer.

Dr. Pietrantonio on Survival Rates in Colorectal Cancer

Filippo Pietrantonio, MD, Department of Medical Oncology, Medical Oncology Unit, Milan Fondazione IRCCS Istituto Nazionale dei Tumori, discusses a nomogram that can predict 12-week survival rates for patients with colorectal cancer (CRC).

The nomogram can be utilized to identify patients with CRC who are at higher risk for death within 12 weeks, explains Pietrantonio. It can also be used as a prognostic method for patient selection, as some of these high-risk patients are enrolled on clinical trials.

Pietrantonio stresses the importance of identifying the correct patients that are able to receive further treatments, given that such stratification is currently done mostly through clinical selection due to a lack of reliability with biomarkers in this space.

Filippo Pietrantonio, MD, Department of Medical Oncology, Medical Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan Fondazione IRCCS Istituto Nazionale dei Tumori, discusses a nomogram that can predict 12-week survival rates for patients with colorectal cancer.

Dr. Pietrantonio on the Design and Rationale Behind a Nomogram to Predict Survival Rates in CRC

Filippo Pietrantonio, MD, Department of Medical Oncology, Medical Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan Fondazione IRCCS Istituto Nazionale dei Tumori, discusses the benefit of a nomogram that can predict 12-week survival rates for patients with colorectal cancer (CRC).  

If this nomogram were to be implemented in clinical trial assessment or inclusion criteria will help enroll patients that can be treated effectively and will most benefit from treatment.

The nomogram relies on four variable that impact survival; ECOG performance status, primary tumor resection, LDH value, peritoneal disease. These variables are very easy to collect in daily clinical practice, said Pietrantonio.

Dr. Filippo Pietrantonio on Using Nomogram for Patient Selection in CRC Trials

Filippo Pietrantonio, MD, Department of Medical Oncology, Medical Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan Fondazione IRCCS Istituto Nazionale dei Tumori, discusses a nomogram that is used to predict 12-week survival rates for patients with colorectal cancer (CRC).

Pietrantonio explains that the nomogram can be utilized to identify patients with CRC who are at higher risk for death within 12 weeks.

Additionally, the nomogram can be used as a prognostication method for patient selection, as some of these high-risk patients are enrolled on clinical trials.

Filippo Pietrantonio, MD, Department of Medical Oncology, Medical Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan Fondazione IRCCS Istituto Nazionale dei Tumori, discusses findings of a clinical trial examining a nomogram used to predict 12-week survival rates for patients with colorectal cancer (CRC).

Author | Filippo Pietrantonio, MD

Articles

New content coming soon, please check back later.